 Home > Medical News > Latest Medical News > State Food and Drug Administration: 20 batches of comfrey and other drugs produced by 9 enterprises such as Zhengzhou Ruilong Pharmaceutical do not meet the regulations

State Food and Drug Administration: 20 batches of comfrey and other drugs produced by 9 enterprises such as Zhengzhou Ruilong Pharmaceutical do not meet the regulations

 Last Update: 2022-09-09
 Source: Internet
 Author: User

Tags

drug hair sample

hyzaar drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

According to the news on the website of the State Food and Drug Administration on August 29, after inspection by 6 drug inspection agencies such as the China Food and Drug Inspection Institute, 20 batches of drugs such as comfrey produced by 9 enterprises such as Zhengzhou Ruilong Pharmaceutical Co.
, Ltd.
did not meet the regulations
.
The relevant information is hereby notified as follows:

First, after the inspection of Fujian Food and Drug Quality Inspection Institute, the 2 batches of dihydroxyprophylline injection labeled as produced by Shanxi Taiyuan Pharmaceutical Co.
, Ltd.
(formerly Taiyuan Pharmaceutical Factory) did not meet the regulations, and the items that did not meet the requirements were visible foreign bodies
.

After inspection by Jilin Provincial Institute of Drug Inspection and Research, the 1 batch of agarwood stagnant pills labeled as produced by Hebei Bian que Pharmaceutical Co.
, Ltd.
did not meet the regulations, and the items that did not meet the regulations were the difference in
loading.

After the inspection of Jiangxi Provincial Institute of Drug Inspection and Testing, the three batches of Huoxiang Zhengqi water marked as produced by Sichuan Tianfu Kangda Pharmaceutical Group Fuqing Pharmaceutical Co.
, Ltd.
and Taiji Group Sichuan Nanchong Pharmaceutical Co.
, Ltd.
do not meet the regulations, and the items that do not meet the requirements are methanol
.

After inspection by the Guangdong Provincial Drug Inspection Institute, the 1 batch of Longze bear bile capsules labeled as produced by Changchun Puhua Pharmaceutical Co.
, Ltd.
does not meet the regulations, and the items that do not meet the requirements are microbial limits
.

After inspection by the China Institute of Food and Drug Control, the 3 batches of chrysanthemums labeled as produced by Yancheng Traditional Chinese Medicine Tablets Co.
, Ltd.
did not meet the regulations, and the items that did not meet the requirements were the prohibited pesticide residues
.

After inspection by the Gansu Provincial Institute of Drug Inspection and Research, the 1 batch of madder marked as produced by Yunnan Jian'antang Biotechnology Co.
, Ltd.
does not meet the regulations, and the items that do not meet the requirements include traits and identification; The 2 batches of madder produced by Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co.
, Ltd.
do not meet the regulations, and the items that do not meet the regulations include traits, identification, total ash, acid insoluble ash, and leachables
.

After the inspection of the China Institute of Food and Drug Control, the 1 batch of comfrey marked as produced by Guilin Zhongnan (Bozhou) Pharmaceutical Technology Co.
, Ltd.
does not meet the regulations, and the non-compliant items are content determination; The 6 batches of comfrey marked as produced by Zhengzhou Ruilong Pharmaceutical Co.
, Ltd.
do not meet the regulations, and the items that do not meet the requirements are traits
.

Second, for the above-mentioned drugs that do not meet the regulations, the drug supervision and management department has required relevant enterprises and units to take risk control measures such as suspension of sales and use, recall, etc.
, to investigate the reasons for the non-compliance and effectively rectify
them.

The State Drug Administration requires the relevant provincial drug supervision and administration departments to organize a case filing and investigation of the suspected illegal acts of the above-mentioned enterprises and units in accordance with the Drug Administration Law of the People's Republic of China, and to disclose the results of
the investigation and handling in accordance with regulations.

Pharmaceuticals

Enterprise enterprise

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.